CJC-1295 & Ipamorelin
How This Peptide Stack Works, Benefits, Dosage and Safety 2026
FDA status (April 2026): CJC-1295 and ipamorelin are not FDA-approved for any indication. Both are classified as Category 2 bulk drug substances under the FDA 503A bulks list, which restricts compounding. Active legal challenges have suspended enforcement of Category 2 restrictions as of early 2026. This status may change. Verify current regulations before pursuing therapy.
CJC-1295 and ipamorelin are two growth hormone secretagogues (GHS) used together to raise circulating growth hormone (GH) and IGF-1. CJC-1295 is a modified GHRH analog. It stimulates sustained GH release from the pituitary gland over days, not hours.
Ipamorelin is a selective ghrelin receptor agonist. It triggers an immediate GH pulse without raising cortisol or other stress hormones.
Combined, they produce both a sustained GH baseline and acute GH spikes. This dual-release profile is unavailable from either peptide alone. Human trials confirm dose-dependent GH and IGF-1 increases. CJC-1295 at 30 to 90 mcg weekly raised GH levels (PMID 16822960). Ipamorelin produced peak GH within one hour (PMID 10411095).
Primary reported outcomes include increased lean muscle mass, reduced body fat, improved sleep quality, and support for sarcopenia management. Both peptides are off-label, not FDA-approved, and subject to compounding regulations.
How CJC-1295 and Ipamorelin Work: Dual-release Growth Hormone Mechanism
The two peptides target different receptors on the pituitary gland. This is why they work better together than alone.
CJC-1295: the sustained signal
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It binds to the GHRH receptor (GHRH-R) on pituitary somatotroph cells and stimulates GH secretion.
What makes CJC-1295 unusual is its DAC (Drug Affinity Complex) modification. DAC extends the peptide’s half-life from approximately 30 minutes (native GHRH) to 6 to 8 days. This means a single dose produces tonic GH elevation for nearly a week, rather than a brief pulse that fades within hours.
Ipamorelin: the acute pulse
Ipamorelin activates a different receptor: GHSR-1a, the growth hormone secretagogue receptor. It mimics ghrelin and triggers a sharp GH spike within 30 to 60 minutes of injection.
Ipamorelin’s key advantage over older GH-releasing peptides (GHRPs) is selectivity. It does not elevate ACTH, cortisol, or prolactin. This cortisol-neutral profile preserves the anabolic-to-catabolic ratio that matters for body composition.
Why the combination matters
CJC-1295 raises the GH floor. Ipamorelin adds peaks on top of it. Together, they create a “tortoise and hare” release pattern: steady sustained elevation plus acute pulses that mimic the body’s natural rhythm.
The downstream pathway runs through IGF-1 (insulin-like growth factor 1). GH stimulates the liver to produce IGF-1, which then drives muscle protein synthesis and fat metabolism regulation. A 2013 trial (PMID 23783614) confirmed dose-dependent IGF-1 increases in healthy adults receiving CJC-1295.
[Placeholder: Dual-Release Mechanism Infographic showing CJC-1295 → GHRH-R → sustained GH release // Ipamorelin → GHSR-1a → acute GH pulse // GH → IGF-1 → muscle and fat outcomes]
Clinical Evidence: What Trials Show About CJC-1295 and Ipamorelin
No published randomized controlled trial has tested CJC-1295 and ipamorelin as a combination. This is a transparency point worth stating clearly. The evidence base comes from separate trials of each peptide.
CJC-1295 human trials
A 2006 study (PMID 16822960) administered CJC-1295 at 30, 60, and 90 mcg per week to healthy adults. Participants showed sustained increases in GH pulsatility and mean GH levels without altering the natural pulsatile pattern. Effects persisted for up to six days after a single dose.
A 2013 follow-up trial (PMID 23783614) confirmed dose-dependent IGF-1 increases in healthy adults. Higher doses produced proportionally greater IGF-1 elevation, supporting the dose-response relationship.
Ipamorelin human trial
A 1999 study of 40 healthy volunteers (PMID 10411095) established that ipamorelin produces peak GH concentration within one hour of administration. The study confirmed selectivity: ipamorelin did not elevate cortisol, ACTH, or prolactin at GH-stimulating doses.
Evidence tier summary
The evidence for GH and IGF-1 elevation is strong (multiple human trials, dose-response confirmed). Evidence for body composition changes is moderate (supported by GH physiology and smaller studies). Evidence for anti-aging or longevity claims is weak (no controlled human data specific to these peptides).
Body Composition Benefits: Muscle Gain, Fat Loss and Results Timeline
GH elevation drives two pathways relevant to body composition.
Muscle gain: GH stimulates collagen synthesis and cellular replication in skeletal muscle. IGF-1 promotes muscle protein synthesis directly. A 2013 trial studied men over 50 receiving GH therapy for six months. Participants showed measurable increases in lean mass and grip strength (PMID 23751216).
Fat loss: GH activates lipolysis, the process of breaking stored fat into free fatty acids for energy. IGF-1 modulates fat metabolism regulation, promoting fat redistribution from visceral to subcutaneous depots. These effects are most pronounced when combined with resistance training.
GH secretagogues support body composition changes but do not replace exercise. Resistance training activates the muscle-building pathway that GH and IGF-1 facilitate. Without training stimulus, results are minimal.
Results timeline (with consistent resistance training)
| Time Period | Observable Outcomes | Evidence Level |
|---|---|---|
| Weeks 1 to 2 | Improved sleep quality, faster recovery between sessions | Strong (GHRH-sleep studies) |
| Weeks 4 to 6 | More defined muscular contour, reduced post-workout soreness | Moderate |
| Weeks 8 to 12 | Measurable body fat reduction, strength gains on compound lifts | Moderate |
| Beyond 12 weeks | Skin quality improvements, sustained body composition changes | Weak to moderate |
Results vary by individual. Age, training history, diet, and compliance all affect the timeline. These outcomes are training-dependent: the peptide stack amplifies the signal, but you supply the stimulus.
Sarcopenia context
Sarcopenia (age-related muscle loss) affects 10 to 16% of adults worldwide (PMID 23751216). After age 30, adults lose 3 to 8% of muscle mass per decade. GH secretagogues may support sarcopenia management when paired with resistance training. Large-scale trials specific to CJC-1295 and ipamorelin for this use do not yet exist.
CJC-1295 and ipamorelin vs other growth hormone secretagogues
Several GH secretagogues exist. This table compares the four most commonly discussed options.
| Feature | CJC-1295 | Ipamorelin | Sermorelin | Tesamorelin |
|---|---|---|---|---|
| Mechanism | GHRH analog (GHRH-R) | Ghrelin analog (GHSR-1a) | GHRH analog (GHRH-R) | GHRH analog (GHRH-R) |
| Half-life | 6 to 8 days (with DAC) | ~2 hours | ~10 to 20 minutes | ~26 minutes |
| Evidence tier | Moderate (2 human trials) | Moderate (1 human trial) | Moderate (multiple trials) | Strong (FDA-approved for one indication) |
| Regulatory status (2026) | Category 2 (enforcement suspended) | Category 2 (enforcement suspended) | Compoundable by prescription | FDA-approved for HIV lipodystrophy |
| Typical monthly cost | $150 to $350 | Included in combo vial | $150 to $300 | $800 to $1,200 |
CJC-1295’s extended half-life is its primary advantage over sermorelin, which requires daily dosing. The CJC-1295 and ipamorelin combination captures both sustained and pulsatile GH patterns. Sermorelin alone provides only the sustained component with a much shorter duration.
Tesamorelin is the only GH secretagogue with an FDA-approved indication (HIV-associated lipodystrophy). It is not approved for general body composition use.
Additional Benefits: Sleep, Injury Recovery and Longevity
Beyond body composition, three secondary benefit domains appear in clinical literature. Each receives an explicit evidence rating.
Sleep quality (strong evidence)
GHRH administration increases slow-wave sleep (deep sleep). Multiple studies from the 1990s established this connection. Slow-wave sleep is when the body performs most tissue repair and GH release peaks naturally.
CJC-1295, as a GHRH analog, may replicate this effect. Many users report improved sleep quality within the first one to two weeks.
Injury recovery (mixed evidence)
A 2020 pilot study on GH peptides in ACL recovery reported positive preliminary results. A 2024 in vitro tendon study found no significant effect. The evidence is genuinely mixed. Do not pursue CJC-1295 and ipamorelin solely for injury recovery.
Anti-aging and longevity (insufficient evidence)
GH declines at approximately 14% per decade after age 30. Some practitioners frame GH secretagogue therapy as “anti-aging.” No controlled human trial has shown that CJC-1295 and ipamorelin reverse biological aging markers. Anecdotal reports of improved skin quality exist but remain unvalidated.
Dosage, Administration and Treatment Protocol
All dosing decisions require supervision by a licensed prescriber. The following reflects commonly reported clinical protocols.
Pre-treatment lab testing
A qualified prescriber typically orders these baseline tests before starting therapy:
- IGF-1 (baseline level to track response)
- Fasting growth hormone
- Complete blood count (CBC)
- Comprehensive metabolic panel
These labs assess candidacy, rule out contraindications, and establish a monitoring baseline for dose titration.
Dosing protocol
| Parameter | Protocol |
|---|---|
| Starting dose | 0.2 mg combined (CJC-1295 + ipamorelin in one vial) |
| Maintenance range | Titrated upward based on IGF-1 response and tolerability |
| Injection frequency | 5 times per week |
| Timing | Nighttime (aligns with natural pulsatile GH release) |
| Cycle structure | 3 months on, 1 month off |
| Administration | Subcutaneous injection (abdomen, thigh, or upper arm) |
| Weight-based adjustment | Common in clinical practice; prescriber discretion |
Cycling (3 months on, 1 month off) prevents receptor desensitization. Without cycling, the pituitary may downregulate its response to the secretagogue signal.
Reconstitution and storage
Both peptides are typically compounded into a single vial. Reconstitution involves adding bacteriostatic water to the lyophilized powder. Follow your pharmacy’s instructions for the exact volume.
Storage: Unreconstituted vials should be refrigerated at 2 to 8 degrees Celsius (NIBSC recommendation). Reconstituted peptide should also be stored at approximately 4 degrees Celsius and used within 28 days. Do not freeze reconstituted peptide.
Avoid repeated freeze-thaw cycles for unreconstituted stock. For travel, use an insulated cooler with ice packs.
Safety Profile: Side Effects, Risks and Contraindications
Side effects are organized by severity to help you and your prescriber assess risk.
Severe risks
Immunogenicity: The FDA has flagged immunogenicity as a risk for both peptides. Your body may mount an immune response to the synthetic peptide. Potential outcomes range from reduced efficacy to anaphylaxis. Prescribers should assess immune history and monitor for allergic reactions.
Cancer contraindication: GH promotes cellular replication. This is beneficial for healthy tissue (muscle, bone, skin) but potentially harmful in the presence of malignancy. CJC-1295 and ipamorelin are contraindicated in patients with active cancer or a history of cancer. This is an absolute contraindication, not a relative one.
IV administration danger: At least one death has been associated with intravenous (not subcutaneous) ipamorelin administration. These peptides are designed for subcutaneous injection only. Never administer intravenously.
Moderate risks
CJC-1295 may cause cardiovascular effects including increased heart rate, facial flushing, and transient hypotension. These effects are typically brief (minutes to hours) and resolve without intervention. Report any chest pain or sustained heart rate elevation to your prescriber immediately.
Mild risks
Injection site reactions (redness, swelling, mild pain) are the most common side effect. Flu-like symptoms (headache, mild fatigue) occur occasionally during the first one to two weeks of therapy.
Research-grade vs pharmaceutical-grade risk
“Research-grade” peptides sold online may contain impurities, incorrect doses, or contaminants. Documented risks include infection and potential genotoxicity from chemical byproducts. Pharmaceutical-grade peptides from accredited compounding pharmacies follow USP purity standards.
Who Should and Should Not Use CJC-1295 and Ipamorelin
Candidates who may benefit
Adults over 40 with body composition goals: Age-related GH decline is measurable and progressive. GH secretagogues may complement resistance training and nutrition.
Individuals at risk for sarcopenia: If you are over 50 and noticing reduced muscle mass or grip strength, GH secretagogue therapy may complement resistance training. Sarcopenia affects 10 to 16% of adults globally.
Adults with growth hormone deficiency (AGHD): AGHD is rare (approximately 1 in 10,000 adults). Causes include traumatic brain injury and pituitary or hypothalamic tumors. Symptoms include increased body fat, reduced stamina, and insulin resistance.
Who should not use these peptides
Active cancer or cancer history: Absolute contraindication. GH-driven cellular replication may promote tumor growth.
Pregnant or breastfeeding individuals: Safety data does not exist for this population.
Competitive athletes under WADA jurisdiction: Both CJC-1295 and ipamorelin are classified as prohibited substances on the WADA Prohibited List under the growth hormone secretagogue category. They are banned both in-competition and out-of-competition. Use constitutes an anti-doping violation.
Individuals with severe needle aversion: These peptides require subcutaneous injection 5 times per week. No oral formulation exists.
How to Access CJC-1295 and Ipamorelin: Regulation, Sources and Quality Standards
The regulatory framework in 2026
The FDA maintains a “503A bulks list” that governs which substances licensed compounding pharmacies can compound. Substances are classified as either Category 1 (compoundable) or Category 2 (restricted pending further evaluation).
CJC-1295 and ipamorelin are both Category 2. In principle, this means compounding pharmacies cannot legally produce them. Active legal challenges filed by compounding pharmacy trade groups have suspended enforcement as of early 2026.
This suspension is not permanent. It may be reversed, extended, or replaced by formal reclassification.
HHS Secretary RFK Jr. announced in February 2026 that approximately 14 of 19 Category 2 peptides may return to Category 1. The official updated list has not been published.
What to look for in a telehealth clinic
If you pursue CJC-1295 and ipamorelin therapy, evaluate providers against these quality signals:
- Live physician consultation (not a questionnaire-only intake)
- Lab assessment required before prescribing (IGF-1, CBC, metabolic panel minimum)
- Accredited compounding pharmacy (503A or 503B license, state board verification available)
- Patient portal with ongoing monitoring and follow-up appointments
Red flags to avoid
Avoid any provider that prescribes after a simple questionnaire with no lab work. Avoid sources that sell peptides without a prescription. Never buy “research-grade” peptides from overseas vendors or unregulated websites.
Conclusion
CJC-1295 and ipamorelin deliver a dual-release GH pattern: sustained baseline elevation plus acute pulses. The combination raises GH and IGF-1 in a dose-dependent, clinically validated manner. Ipamorelin’s cortisol-neutral selectivity preserves hormonal balance for body composition goals.
Evidence supports GH/IGF-1 elevation (strong), body composition with training (moderate), and sleep benefits (strong). Recovery evidence is mixed. Anti-aging claims remain unvalidated.
Access requires a licensed clinician and an accredited compounding pharmacy. Verify the current 2026 regulatory status before starting. Discuss baseline labs, contraindications, and monitoring with your prescriber.
Frequently Asked Questions
Is the CJC-1295 and ipamorelin combination legal in 2026?
Both peptides are classified as Category 2 bulk drug substances under the FDA 503A bulks list. Active legal challenges have suspended enforcement of Category 2 compounding restrictions as of early 2026. Access through a licensed clinician and accredited compounding pharmacy is currently the legal pathway. This status is subject to change, so verify regulations before starting therapy.
How long does it take to see results from CJC-1295 and ipamorelin?
Most users report improved sleep and faster recovery within one to two weeks. More defined muscular contour typically appears within four to six weeks with consistent resistance training. Measurable fat reduction and strength gains usually require eight to twelve weeks. Skin quality improvements may follow after that. Results depend on training compliance, diet, and individual physiology.
Can competitive athletes use CJC-1295 and ipamorelin?
No. Both peptides are classified as prohibited substances by WADA under the growth hormone secretagogue category. They are banned in-competition and out-of-competition. Use by athletes under WADA jurisdiction constitutes an anti-doping violation. This applies regardless of prescription status.
What lab tests are needed before starting CJC-1295 and ipamorelin?
A qualified prescriber typically orders baseline IGF-1, fasting growth hormone, complete blood count (CBC), and a comprehensive metabolic panel. These tests assess candidacy and identify contraindications. They also establish a reference point for monitoring your response to dose titration.
What is the difference between CJC-1295 with DAC and without DAC?
The DAC (Drug Affinity Complex) modification extends CJC-1295’s half-life from approximately 30 minutes to 6 to 8 days. The DAC version requires less frequent dosing and produces sustained tonic GH elevation. The non-DAC version (also called Modified GRF 1-29) requires more frequent dosing. It maintains pulsatile GH release patterns closer to the body’s natural rhythm.
Is CJC-1295 and ipamorelin effective specifically for weight loss?
GH elevation stimulates lipolysis (fat breakdown) and IGF-1 modulates fat metabolism. These mechanisms contribute to body fat reduction, particularly when combined with resistance training. However, “weight loss” is a secondary outcome. The primary documented benefits are lean mass gain and fat redistribution rather than scale weight reduction. If significant weight loss is your primary goal, FDA-approved GLP-1 medications have stronger evidence.
This article is for informational purposes only and does not constitute medical advice. CJC-1295 and ipamorelin are not FDA-approved for any indication. Consult a licensed healthcare provider before starting any peptide therapy. Individual results vary based on medical history, dosage, and lifestyle factors.
peptides.io is part of the Medaly longevity discovery platform.